Complete financial analysis of Check-Cap Ltd. (CHEK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Check-Cap Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- ATW Tech Inc. (ATW.V) Income Statement Analysis – Financial Results
- Learning Technologies Group plc (LTTHF) Income Statement Analysis – Financial Results
- Coastal Capital Acquisition Corp. (CCAJ) Income Statement Analysis – Financial Results
- Repay Holdings Corporation (RPAYW) Income Statement Analysis – Financial Results
- Corning Natural Gas Holding Corporation (CNIGO) Income Statement Analysis – Financial Results
Check-Cap Ltd. (CHEK)
About Check-Cap Ltd.
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 244.00K | 173.00K | -788.00K | 0.00 | 0.00 |
| Cost of Revenue | 212.00K | 405.00K | 205.00K | 148.00K | 115.00K | 148.00K | 157.00K | 130.00K | 92.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -212.00K | -405.00K | -205.00K | -148.00K | -115.00K | -148.00K | -157.00K | 114.00K | 81.00K | -788.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 46.72% | 46.82% | 100.00% | 0.00% | 0.00% |
| Research & Development | 8.29M | 14.27M | 12.35M | 10.01M | 10.47M | 7.62M | 6.84M | 5.49M | 5.84M | 3.11M | 2.66M | 2.69M |
| General & Administrative | 9.55M | 5.76M | 4.97M | 3.92M | 3.60M | 3.45M | 3.16M | 3.56M | 6.62M | 1.70M | 1.08M | 1.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.00K | 7.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 9.55M | 5.76M | 4.97M | 3.92M | 3.60M | 3.45M | 3.16M | 3.57M | 6.63M | 1.70M | 1.08M | 1.20M |
| Other Expenses | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 275.00K | 7.00K | 7.00K |
| Operating Expenses | 19.29M | 20.03M | 17.32M | 13.93M | 14.07M | 11.06M | 10.00M | 9.06M | 12.46M | 4.81M | 3.75M | 3.90M |
| Cost & Expenses | 19.29M | 20.03M | 17.32M | 13.93M | 14.07M | 11.06M | 10.00M | 9.06M | 12.46M | 4.81M | 3.75M | 3.90M |
| Interest Income | 1.77M | 926.00K | 119.00K | 69.00K | 245.00K | 243.00K | 66.00K | 139.00K | 61.00K | 10.00K | 59.00K | 183.00K |
| Interest Expense | 13.00K | 12.00K | 13.00K | 12.00K | 8.00K | 7.00K | 7.00K | 7.00K | 47.00K | 5.00K | 0.00 | 6.00K |
| Depreciation & Amortization | 212.00K | 405.00K | 205.00K | 148.00K | 115.00K | 148.00K | 157.00K | 130.00K | 92.00K | 78.00K | 77.00K | 73.00K |
| EBITDA | -17.65M | -18.69M | -16.98M | -13.69M | -13.95M | -10.44M | -9.84M | -8.93M | -12.23M | -4.46M | -3.90M | -3.84K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,660.66% | -7,150.87% | 506.73% | 0.00% | 0.00% |
| Operating Income | -19.29M | -20.03M | -17.32M | -13.93M | -14.07M | -11.06M | -10.00M | -9.06M | -12.46M | -4.81M | -3.74M | -3.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,713.93% | -7,204.05% | 610.41% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.72M | 926.00K | 119.00K | 86.00K | 233.00K | 473.00K | 236.00K | 244.00K | 173.00K | 3.93M | 604.00K | 187.00K |
| Income Before Tax | -17.57M | -19.11M | -17.20M | -13.85M | -13.84M | -10.59M | -9.77M | -8.82M | -12.29M | -4.08M | -4.00M | -3.72M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,613.93% | -7,104.05% | 517.26% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 146.00K | -110.00K | -85.00K | -240.00K | -1.00K | 6.00K | 8.00K | 0.00 | 734.00K | 243.00K | 6.00K |
| Net Income | -17.57M | -19.25M | -17.09M | -13.76M | -13.60M | -10.59M | -9.77M | -8.83M | -12.29M | -4.08M | -4.00M | -3.72M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,617.21% | -7,104.05% | 517.26% | 0.00% | 0.00% |
| EPS | -3.00 | -3.39 | -4.13 | -9.07 | -34.05 | -52.19 | -134.31 | -146.10 | -247.49 | -82.10 | -160.71 | -149.69 |
| EPS Diluted | -3.00 | -3.39 | -4.13 | -9.07 | -34.05 | -52.19 | -134.31 | -146.10 | -247.49 | -82.10 | -160.71 | -149.69 |
| Weighted Avg Shares Out | 5.85M | 5.67M | 4.14M | 1.52M | 399.30K | 202.90K | 72.75K | 60.41K | 49.66K | 49.64K | 24.86K | 24.86K |
| Weighted Avg Shares Out (Dil) | 5.85M | 5.67M | 4.14M | 1.52M | 399.30K | 202.90K | 72.75K | 60.41K | 49.66K | 49.64K | 24.86K | 24.86K |
Check-Cap Reports Fourth Quarter and Full Year 2020 Financial Results
ISFIYA, Israel, March 19, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free, screening test to detect polyps before they...
CHEK Stock Price Falls Over 10% Pre-Market: Why It Happened
The stock price of Check Cap Ltd (NASDAQ: CHEK) fell by over 10% pre-market. This is why it happened.
CHEK Stock: The Big FDA News That Has Check-Cap Shares Skyrocketing Today
Check-Cap (CHEK) stock is heading higher on Monday after the company announced approval from the FDA for one of its devices. The post CHEK Stock: The Big FDA News That Has Check-Cap Shares Skyrocketing Today appeared first on InvestorPlace.
CHEK Stock Price Increases Over 130% Pre-Market: Why It Happened
The stock price of Check Cap Ltd (NASDAQ: CHEK) has increased by over 130% pre-market. This is why it happened.
FDA Signs Off Check-Cap's Pivotal Study For Capsule-Based Colorectal Cancer Screening Technology
Check-Cap Ltd (NASDAQ: CHEK) stock is moving higher on heavy volume in the premarket session after the FDA approved its Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. C-Scan is the company's capsule-based screening technology...
Check-Cap: Come Back In A Year
The technology appears safe, but performance versus standard of care requires a larger, expensive study. It will take a couple years to get readouts from the pivotal US study, providing a lack of catalyst.
Check-Cap Ltd.: 6 Things for Potential CHEK Stock Investors to Know About the Biotech Company
Check-Cap Ltd. (CHEK) stock is on the rise Monday despite a lack of news from the maker of the C-Scan colorectal cancer screening device.
Energy stocks among top premarket losers
Check-Cap (NASDAQ:CHEK) -54% on $4M direct offering.Invesco Mortgage Capital (NYSE:IVR) -32%.Akazoo S.A. (NASDAQ:SONG) -24%.Penn Virginia (NASDAQ:PVAC) -17%.California Resources (NYSE:CRC) -17%.Matado
Source: https://incomestatements.info
Category: Stock Reports